Expression profile analysis for epithelial-mesenchymal transition of breast cancer cell line DKTA based on microarray data

Objective: This study aimed to explore the molecular mechanisms of epithelial-mesenchymal transition (EMT) in breast cancer cells. Materials and Methods: GSE33146 microarray data downloaded from Gene Expression Omnibus (GEO). Gene ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analysis of differentially expressed genes (DEGs) was performed, followed by functional annotation. Protein-protein interaction (PPI) network was constructed, and then five modules were mined for functional analysis. Results: A total of 507 DEGs including 229 up- and 278 down-regulated DEGs were screened between pre- and post-EMT samples. The screened DEGs mainly enriched in KEGG pathways, such as focal adhesion (p = 0.017), TGF-beta signaling pathway (p = 0.028), and ECM-receptor interaction (p = 6.89E-04), and also enriched in some GO terms such as regulation of cell proliferation (p = 2.48E-06) and ectoderm development (p = 2.76E-08). By functional analysis of DEGs, a total of ten proto-oncogenes including PBX1, MYBL1, MET, VAV3, and MYC, and 42 anti-oncogenes including TXNIP, TPM1, TMEFF2, TP63, and STEAP3 were obtained. Seven identified DEGs including SNCG, PTHLH, OAS1, KRT5, ITGB4, CHRM3, and CBLB were obtained. The constructed PPI network contained 192 nodes and 293 edges. A total of five models were screened from PPI network. DEGs in five modules were enriched in various functions, such as response to virus (FDR = 15.2), G-protein coupled receptor protein signaling pathway (FDR = 16.21), focal adhesion (FDR = 5.52E-05), and ECM-receptor interaction (FDR = 6.56E-07). Conclusions: The identified DEGs, especially in five modules, such as OAS1, IFI27, LPAR1, PTGFR, ITGB4, and ITGA6 might participate in EMT process for breast cancer cell lines DKTA.

Breast cancer; Epithelial-mesenchymal transition; PPI network

[1] Al-Hajj M., Wicha M.S., Benito-Hernandez A., Morrison S.J., Clarke M.F.: “Prospective identification of tumorigenic breast cancer cells”. Proc. Natl. Acad. Sci. U S A, 2003, 100, 3983.

[2] Creighton C.J., Chang J.C., Rosen J.M.: “Epithelial-mesenchymal transition (EMT) in tumor-initiating cells and its clinical implications in breast cancer”. J. Mammary Gland Biol. Neoplasia, 2010, 15, 253.

[3] Christiansen J.J., Rajasekaran A.K.: “Reassessing epithelial to mesenchymal transition as a prerequisite for carcinoma invasion and metastasis”. Cancer Res., 2006, 66, 8319.

[4] Friedl P., Wolf K.: “Tumour-cell invasion and migration: diversity and escape mechanisms”. Nat. Rev. Cancer, 2003, 3, 362.

[5] Gupta G.P., Massague J.: “Cancer metastasis: building a framework”. Cell, 2006, 127, 679.

[6] Zavadil J., Haley J., Kalluri R., Muthuswamy S.K., Thompson E.: “Epithelial-mesenchymal transition”. Cancer Res., 2008, 68, 9574.

[7] Korpal M., Lee E.S., Hu G., Kang Y.: “The miR-200 family inhibits epithelial-mesenchymal transition and cancer cell migration by direct targeting of E-cadherin transcriptional repressors ZEB1 and ZEB2”. J. Biol. Chem., 2008, 283, 14910.

[8] WORK B.R.O.I.: “The relationship of Epithelial-Mesenchymal Transition marker, SNAIL with the invasiveness and infiltration in Ameloblastoma, Keratocystic Odontogenic Tumor and Oral Squamous Cell Carcinoma-A Comparative Immunohistochemical Study”.

[9] De Craene B., Berx G.: “Regulatory networks defining EMT during cancer initiation and progression”. Nat. Rev. Cancer, 2013, 13, 97.

[10] Mulholland D.J., Kobayashi N., Ruscetti M., Zhi A., Tran L.M., Huang J., et al.: “Pten loss and RAS/MAPK activation cooperate to promote EMT and metastasis initiated from prostate cancer stem/progenitor cells”. Cancer Res., 2012, 72, 1878.

[11] Thiery J.P.: “Epithelial–mesenchymal transitions in development and pathologies”. Curr. Opin. Cell Biol., 2003, 15, 740.

[12] Barrallo-Gimeno A., Nieto M.A.: “The Snail genes as inducers of cell movement and survival: implications in development and cancer”. Development, 2005, 132, 3151.

[13] Vincan E., Barker N.: “The upstream components of the Wnt signalling pathway in the dynamic EMT and MET associated with colorectal cancer progression”. Clin. Exp. Metastasis, 2008, 25, 657.

[14] Smith A.L., Iwanaga R., Drasin D.J., Micalizzi D.S., Vartuli R.L., Tan A.C., et al.: “The miR-106b-25 cluster targets Smad7, activates TGF-beta signaling, and induces EMT and tumor initiating cell characteristics downstream of Six1 in human breast cancer”. Oncogene, 2012, 31, 5162.

[15] Gautier L., Cope L., Bolstad B.M., Irizarry R.A.: “affy—analysis of Affymetrix GeneChip data at the probe level”. Bioinformatics, 2004, 20, 307.

[16] Irizarry R.A., Hobbs B., Collin F., Beazer-Barclay Y.D., Antonellis K.J., Scherf U., et al.: “Exploration, normalization, and summaries of high density oligonucleotide array probe level data”. Biostatistics, 2003, 4, 249.

[17] Huang da W., Sherman B.T., Lempicki R.A.: “Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources”. Nat. Protoc., 2009, 4, 44.

[18] Ashburner M., Ball C.A., Blake J.A., Botstein D., Butler H., Cherry J.M., et al.: “Gene ontology: tool for the unification of biology. The Gene Ontology Consortium”. Nat. Genet., 2000, 25, 25.

[19] Kanehisa M., Goto S.: “KEGG: kyoto encyclopedia of genes and genomes”. Nucleic Acids Res., 2000, 28, 27.

[20] Zhao M., Sun J., Zhao Z.: “TSGene: a web resource for tumor suppressor genes”. Nucleic Acids Res., 2013, 41, D970.

[21] Chen J.S., Hung W.S., Chan H.H., Tsai S.J., Sun H.S.: “In silico identification of oncogenic potential of fyn-related kinase in hepatocellular carcinoma”. Bioinformatics, 2013, 29, 420.

[22] Franceschini A., Szklarczyk D., Frankild S., Kuhn M., Simonovic M., Roth A., et al.: “STRING v9.1: protein-protein interaction networks, with increased coverage and integration”. Nucleic Acids Res., 2013, 41, D808.

[23] Adamcsek B., Palla G., Farkas I.J., Derenyi I., Vicsek T.: “CFinder: locating cliques and overlapping modules in biological networks”. Bioinformatics, 2006, 22, 1021.

[24] Ghoussaini M., Fletcher O., Michailidou K., Turnbull C., Schmidt M.K., Dicks E., et al.: “Genome-wide association analysis identifies three new breast cancer susceptibility loci”. Nature Genet., 2012, 44, 312.

[25] Li S., Xie Y., Zhang W., Gao J., Wang M., Zheng G., et al.: “Interferon alpha-inducible protein 27 promotes epithelial-mesenchymal transition and induces ovarian tumorigenicity and stemness”. J Surg Res, 2014.

[26] Santen G.W., Aten E., Sun Y., Almomani R., Gilissen C., Nielsen M., et al.: “Mutations in SWI/SNF chromatin remodeling complex gene ARID1B cause Coffin-Siris syndrome”. Nature Genet., 2012, 44, 379.

[27] Harma V., Virtanen J., Makela R., Happonen A., Mpindi J.P., Knuuttila M., et al.: “A comprehensive panel of three-dimensional models for studies of prostate cancer growth, invasion and drug responses”. PLoS One, 2010, 5, e10431.

[28] Birnbaum D.J., Mamessier E., Birnbaum D.: “The emerging role of the TGFβ tumor suppressor pathway in pancreatic cancer”. Cell Cycle, 2012, 4, 2012.

[29] Bianchi A., Gervasi M.E., Bakin A.V.: “Role of β5-integrin in epithelial-mesenchymal transition in response to TGF-β”. Cell Cycle, 2010, 9, 1647.

[30] Ruisanchez E., Dancs P., Kerek M., Nemeth T., Farago B., Balogh A., et al.: “Lysophosphatidic acid induces vasodilation mediated by LPA1 receptors, phospholipase C, and endothelial nitric oxide synthase”. FASEB J., 2014, 28, 880.

[31] Kuriyama S., Theveneau E., Benedetto A., Parsons M., Tanaka M., Charras G., et al.: “In vivo collective cell migration requires an LPAR2-dependent increase in tissue fluidity”. J. Cell Biol., 2014, 206, 113.

[32] Jahn S.C., Law M.E., Corsino P.E., Parker N.N., Pham K., Davis B.J., et al.: “An in vivo model of epithelial to mesenchymal transition reveals a mitogenic switch”. Cancer Lett., 2012, 326, 183.

[33] Chan T., Fang F., Turcan S.: “Epigenomic markers of cancer metastasis”. Ed., Google Patents, 2011.

[34] Nakano A., Pulkkinen L., Murrell D., Rico J., Lucky A.W., Garzon M., et al.: “Epidermolysis bullosa with congenital pyloric atresia: novel mutations in the beta 4 integrin gene (ITGB4) and genotype/phenotype correlations”. Pediatr. Res., 2001, 49, 618.

[35] Ferraro A., Kontos C., Boni T., Bantounas I., Siakouli D., Kosmidou V., et al.: “Epigenetic regulation of miR-21 in colorectal cancer: ITGB4 as a novel miR-21 target and a three-gene network (miR-21- ITGΒ4-PCDC4) as predictor of metastatic tumor potential”. Epigenetics, 2013, 9, 129.

[36] Drake J.M., Barnes J.M., Madsen J.M., Domann F.E., Stipp C.S., Henry M.D.: “ZEB1 coordinately regulates laminin-332 and β4 integrin expression altering the invasive phenotype of prostate cancer cells”. J. Biol. Chem., 2010, 285, 33940.

[37] Carroll D.K., Carroll J.S., Leong C.O., Cheng F., Brown M., Mills A.A., et al.: “p63 regulates an adhesion programme and cell survival in epithelial cells”. Nat. Cell Biol., 2006, 8, 551.

[38] Choong L.Y., Lim S., Chong P.K., Wong C.Y., Shah N., Lim Y.P.: “Proteome-wide profiling of the MCF10AT breast cancer progression model”. PloS One, 2010, 5, e11030.

[39] Cicchini C., Laudadio I., Citarella F., Corazzari M., Steindler C., Conigliaro A., et al.: “TGFβ-induced EMT requires focal adhesion kinase (FAK) signaling”. Exp. Cell Res., 2008, 314, 143.